Erratum: Hemodynamic Markers and Subclinical Atherosclerosis in Postmenopausal Women with Primary Hyperparathyroidism (Journal of Clinical Endocrinology and Metabolism (2014) 99:8 (2704-2711) DOI: 10.1210/jc.2013-4273);Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2704-2711

  Stamatelopoulos, Kimon ^a   Athanasouli, Fani ^a   Pappa, Theodora ^a   Labrinoudaki, Irene ^a   Papamichael, Christos ^a   Polymeris, Antonis ^a   Georgiopoulos, Georgios ^a   Vemmou, Anastasia ^a   Sarika, Leda ^a   Terpos, Evangelos ^a   Alevizaki, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCIUM; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AORTA PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY PULSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FEMORAL ARTERY; FLOW MEDIATED ENDOTHELIUM DEPENDENT VASODILATION; GLUCOSE BLOOD LEVEL; HEART HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFLECTED WAVE; SUBCLINICAL ATHEROSCLEROSIS; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL;

AGED; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEMODYNAMICS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; PARATHYROID HORMONE; POSTMENOPAUSE; PULSE WAVE ANALYSIS; VITAMIN D;

EID: 84905851682     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2019-00730     Document Type: Erratum

References (40)

1. Vassalle C, Simoncini T, Chedraui P, Perez-Lopez FR. Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol. 2012;28:746-751.
2. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis. 2012;225:180-186.
3. Lambrinoudaki I, Armeni E, Georgiopoulos G, et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int J Cardiol. 2013;164:70-76.
4. Choi HS, Kim SH, Rhee Y, Cho MA, Lee EJ, Lim SK. Serum parathyroid hormone is associated with carotid intima-media thickness in postmenopausal women. Int J Clin Pract. 2008;62:1352-1357.
5. Pirro M, Manfredelli MR, Helou RS, et al. Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency. J Atheroscler Thromb. 2012;19:924-931.
6. Slinin Y, Blackwell T, Ishani A, Cummings SR, Ensrud KE. Serum calcium, phosphorus and cardiovascular events in post-menopausal women. Int J Cardiol. 2011;149:335-340.
7. Silverberg SJ, Walker MD, Bilezikian JP. Asymptomatic primary hyperparathyroidism. J Clin Densitom. 2013;16:14-21.
8. Reis JP, von Muhlen D, Kritz-Silverstein D, Wingard DL, Barrett- Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007;30:1549-1555.
9. Montalcini T, Terracciano R, Romeo S, et al. Postmenopausal women with carotid atherosclerosis: potential role of the serum calcium levels. Nutr Metab Cardiovasc Dis. 2013;23:1141-1146.
10. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73:30-34.
11. Leifsson BG, Ahren B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab. 1996;81:2149-2153.
12. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil. 2004;11:69-74.
13. Lundgren E, Hagstrom EG, Lundin J, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg. 2002;26:931-936.
14. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, et al. Prolactin and preclinical atherosclerosis in menopausalwomenwith cardiovascular risk factors. Hypertension. 2009;54:98-105.
15. Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis. 2010;212:305-309.
16. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:3849-3856.
17. Broulik PD, Broulikova A, Adamek S, et al. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol. 2011;2011:309068.
18. Letizia C, Ferrari P, Cotesta D, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19:901-906.
19. Nuzzo V, Tauchmanova L, Fonderico F, et al. Increased intimamedia thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol. 2002;147:453-459.
20. Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85:3515-3519.
21. Ring M, Farahnak P, Gustavsson T, Nilsson IL, Eriksson MJ, Caidahl K. Arterial structure and function in mild primary hyperparathyroidism is not directly related to parathyroid hormone, calcium, or vitamin D. PLoS One. 2012;7:e39519.
22. Sabovic M, Safar ME, Blacher J. Is there any additional prognostic value of central blood pressure wave forms beyond peripheral blood pressure? Curr Pharm Des. 2009;15:254-266.
23. Fardella C, Rodriguez-Portales JA. Intracellular calcium and blood pressure: comparison between primary hyperparathyroidism and essential hypertension. J Endocrinol Invest. 1995;18:827-832.
24. Gennari C, Nami R, Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Miner Electrolyte Metab. 1995;21:77-81.
25. Schiffl H, Sitter T, Lang SM. Noradrenergic blood pressure dysregulation and cytosolic calcium in primary hyperparathyroidism. Kidney Blood Press Res. 1997;20:290-296.
26. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828-832.
27. Walker MD, Cong E, Kepley A, et al. Association between serum 25-hydroxyvitamin d level and subclinical cardiovascular disease in primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99: 671-680.
28. Chuang SY, Hsu PF, Chang HY, Bai CH, Yeh WT, Pan HW. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the Cardiovascular Disease Risk Factors Two-Township Study. Am J Hypertens. 2013;26:657-664.
29. Christensen MH, Dankel SN, Nordbo Y, et al. Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLoS One. 2011;6:e20481.
30. Safley SA, Villinger F, Jackson EH, Tucker-Burden C, Cohen C, Weber CJ. Interleukin-6 production and secretion by human parathyroids. Clin Exp Immunol. 2004;136:145-156.
31. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
32. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
33. Rosa J, Raska I Jr, Wichterle D, et al. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res. 2011;34:296-300.
34. Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F, Lumachi F. Ultrasound evaluation of carotid artery in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:2096-2099.
35. Neunteufl T, Heher S, Prager G, et al. Effects of successful parathyroidectomy on altered arterial reactivity in patients with hypercalcaemia: results of a 3-year follow-up study. Clin Endocrinol (Oxf). 2000;53:229-233.
36. Schillaci G, Pucci G, PirroM, et al. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis. 2011;218:96-101.
37. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77:93-100.
38. Lips P. VitaminDdeficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
39. Papapetrou PD, Triantaphyllopoulou M, Karga H, et al. Vitamin D deficiency in the elderly in Athens, Greece. J Bone Miner Metab. 2007;25:198-203.
40. Tassone F, Gianotti L, Baffoni C, et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin Endocrinol (Oxf). 2013;79:784-790.